Urothelial Bladder Cancer | Beyond The Guidelines: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Urothelial Bladder Cancer

Featuring perspectives from Prof Sia Daneshmand, Dr Joshua J Meeks, Dr Matthew Milowsky and Prof J Alfred Witjes, moderated by Dr Arlene Siefker‑Radtke, including the following topics: Introduction (0:00) Current Role of Anti-PD-1/PD-L1 Antibodies in the Treatment of Non-Muscle-Invasive Bladder Cancer — Joshua J Meeks, MD, PhD (2:49) Contemporary Management of Muscle-Invasive Bladder Cancer — J Alfred Witjes, MD, PhD (26:30) Novel Strategies Under Investigation for Nonmetastatic Urothelial Bladder Cancer (UBC) — Sia Daneshmand, MD (48:02) Current and Future Up-Front Management of Metastatic UBC (mUBC) — Matthew Milowsky, MD (1:12:26) Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Arlene Siefker-Radtke, MD (1:33:25) CME information and select publications